This study is currently not recruiting participants.

A 6-Month Multicenter Randomized Open-label Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is to compare the safety and benefit of a new and stronger dose of insulin glargine (named HOE901-U300) with that of the currently marketed insulin glargine U100, (also known as Lantus?) in patients with type 1 diabetes mellitus.

Description

The purpose of this study is to compare the safety and benefit of a new and stronger dose of insulin glargine (named HOE901-U300) with that of the currently marketed insulin glargine U100, (also known as Lantus?) in patients with type 1 diabetes mellitus.

Details
Condition Diabetes - Type I
Age 18years - 100years
Clinical Study IdentifierTX2913
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.